

Sorrento Therapeutics Logo

Sorrento Therapeutics CEO Dr. Henry Ji Invited to the Fourth International Vatican Conference on “Unite to Cure”

April 23, 2018

SAN DIEGO, April 23, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) ("Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, has been invited to participate as an expert panelist at the Fourth International Vatican Conference, in Vatican City, Friday, April 27th (11:25 AM GMT+1) on the topic of "Preparing for the future in Cell Therapy" (<http://vaticanconference2018.com>)

The global health care conference was started eight years ago. It aims to unite the world's thought leaders across all disciplines to engage in a powerful conversation about the future of medicine.

Dr. Ji will share his vision for the future of cellular immunotherapy using Sorrento's anti-CD38 and anti-BCMA CAR-T cell therapy programs for treatment of Multiple Myeloma as examples. He will cover breakthrough approaches to generate CAR-bearing immune cells for both hematological malignancies and solid tumors. Dr. Ji will also discuss the utilization of allogeneic cell sources, including placental immune cells as well as gamma/delta T cells, for improving patient access and potentially reducing cost of cell therapies. Here, Dr. Ji will use Sorrento's and its partner Celularity's programs as examples to address scalability of producing allogeneic "off-the-shelf" immune cells and its potential impact on the regulatory path of cellular immunotherapies.

"We are honored to be guests of this highly-respected council," stated Dr. Henry Ji. "We look forward to productive and stimulating exchanges with our peers and contributing to the advancement of the cell therapy field."

About Sorrento Therapeutics, Inc.

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal multipronged approach to fighting cancer is made possible by its' extensive immuno-oncology platforms, including key assets such as fully human antibodies ("G-MAB™ library"), clinical stage immuno-cellular therapies ("CAR-T"), intracellular targeting antibodies ("ITAbs"), antibody-drug conjugates ("ADC"), and clinical stage oncolytic virus ("Sephrevir®").

Sorrento's commitment to life-enhancing therapies for cancer patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule in Resiniferatoxin ("RTX") and ZTlido™. Resiniferatoxin is completing a phase IB trial in terminal cancer patients. ZTlido was approved by US FDA on 02/28/18.

For more information visit www.sorrentotherapeutics.com

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the expectations for Sorrento's and its subsidiaries' technologies and product candidates. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's and its subsidiaries' technologies and prospects, including Sorrento's anti-CD38 and anti-BCMA cell therapy and CAR and CAR-T programs and drug products; risks related to seeking regulatory approvals and conducting clinical trials; and other risks that are described in Sorrento's most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2017, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Media and Investor Relations

Contact: Alexis Nahama, DVM (VP Corporate Development)

Telephone: 1.858.203.4120

Email: mediarelations@sorrentotherapeutics.com

Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

ZTlido™ and G-MAB™ are trademarks owned by Celularity Pharmaceuticals, Inc. and Sorrento, respectively.

Sephrevir® is a registered trademark of Virttu Biologics Limited, a wholly-owned subsidiary of TNK Therapeutics, Inc. and part of the group of companies owned by Sorrento Therapeutics, Inc.

All other trademarks are the property of their respective owners.

© 2018 Sorrento Therapeutics, Inc. All Rights Reserved.

 Primary Logo

Source: Sorrento Therapeutics, Inc.